Applications of positron emission tomography in psychiatry

Seminars in Nuclear Medicine

Volumn 33, Issue 2, 2003, Pages 129-135

  Parsey, Ramin V ^b   Mann, J John ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; 3 METHYLSPIPERONE; CARBON 11; FLUORODEOXYGLUCOSE F 18; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; OXYGEN 15; PINDOLOL; RACLOPRIDE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; WATER;

ARTICLE; BRAIN BLOOD FLOW; BRAIN MAPPING; BRAIN METABOLISM; DIAGNOSTIC IMAGING; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; HUMAN; MOOD DISORDER; NEUROANATOMY; NEUROPATHOLOGY; NEUROTRANSMITTER RELEASE; OBSESSIVE COMPULSIVE DISORDER; POSITRON EMISSION TOMOGRAPHY; PROTEIN SECRETION; PSYCHIATRIC DIAGNOSIS; QUANTITATIVE ANALYSIS; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SEROTONIN RELEASE; TREATMENT OUTCOME;

EID: 0038612805     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2003.127302     Document Type: Article

References (75)

1. Arango V, Underwood MD, Mann JJ: Postmortem findings in suicide victims: Implications for in vivo studies. Ann NY Acad Sci: The Neurobiology of Suicide: From the Bench to the Clinic 836:269-287, 1997
2. Farde L, Hall H, Ehrin E, et al: Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science JI - Sci 231:258-261, 1986
3. Seeman P, Kapur S: Schizophrenia: More dopamine, more D2 receptors. Proc Natt acad Aci USA 97:7673-7675, 2000
4. Post RM, DeLisi LE, Holcomb HH, et al: Glucose utilization in the temporal cortex of affectively ill patients: Positron emission tomography. Biol Psychiatr 22:545-553, 1987
5. Buchsbaum MS, Kesslak JP, Lynch G, et al: Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Preliminary studies. Arch Gen Psychiatry 48:840-847, 1991
6. Mann JJ, Malone KM, Diehl DJ, et al: Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. J Cerebr Blood Flow Metab 15:S94, 1995 (abstr)
7. Delgado PL, Price LH, Miller HL, et al: Serotonin and the neurobiology of depression: Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychia 51:865-874, 1994
8. Mayberg HS, Liotti M, Brannan SK, et al: Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness. Am Psychiatr 156:675-682, 1999
9. Berman KF, Doran AR, Pickar D, et al: Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation. Br J Psychiatr 162:183-192, 1993
10. Frith CD, Friston KJ, Liddle PF, et al: Willed action and the prefrontal cortex in man: A study with PET. Proceed Royal Soc Lond B Biol Sci (London) 244:241-246, 1991
11. Soares JC, Mann JJ: The anatomy of mood disorders - review of structural neuroimaging studies [see comments]. Biol Psychiatr 41:86-106, 1997
12. Soares JC, Mann JJ: The functional neuroanatomy of mood disorders. J Psychiatr Res 31:393-432, 1997
13. Bechara A, Damasio H: Decision-making and addiction (part I): Impaired activation of somatic states in substance dependent individuals when pondering decisions with negative future consequences. Neuropsychologia 40:1675-1689, 2002
14. Damasio H, Grabowski T, Frank R, et al: The return of Phineas Gage et al: Clues about the brain from the skull of a famous patient. Science J1-Sci 264:1102-1105, 1994
15. Mann JJ, Malone KM, Diehl DJ, et al: Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatr 153:174-182, 1996
16. Drevets WC, Videen TO, Price JL, et al: A functional anatomical study of unipolar depression. J Neurosci 12:3628-3641, 1992
17. Botteron KN, Raichle ME, Drevets WC, et al: Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatr 51:342-344, 2002
18. Bremner JD, Vythilingam M, Vermetten E, et al: Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatr 51:273-279, 2002
19. Nobler MS, Sackeim HA, Prohovnik I, et al: Regional cerbral blood flow in mood disorders III. Effects of treatment and clinical response in depression and mania. Arch Gen Psychiatr 51:884-897, 1994
20. Nobler MS, Oquendo MA, Kegeles LS, et al: Decreased regional brain metabolism following electroconvulsive therapy. Am Psychiatr 158:305-308, 2001
21. Myers JE, Mieczkowski TA, Perel J, et al: Abnormal behavioral responses to fenfluramine in patients with affective and personality disorders: Correlation with increased serotonergic responsivity. Bio Psychiatr 35:112-120, 1994
22. McBride PA, DeMeo MD, Sweeney JA, et al: Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist d1-fenfluramine in adults with obsessive-compulsive disorder. Biol Psychiatr 31:19-34, 1992
23. Magistretti PJ, Pellerin I: Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging, Philos Trans Roy Soc Lond B Biol Sci 354:1155-63, 1999
24. Shulman RG: Functional imaging studies: Linking mind and basic neuroscience. Am J Psychiatr 158:11-20, 2001
25. Buchsbaum MS: Positron emission tomography in schizophrenia, in Meltzer HY (ed): Psychopharmacology. The Third Generation of Progress. New York, Raven Press 783-792, 1987
26. Sedvall G: The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology 7:41-54, 1992
27. Ingvar DH, Franzen G: Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 50:425-462, 1974
28. Baxter LR, Jr., Phelps ME, Mazziotta JC, et al: Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatr 42:441-447, 1985
29. Baxter LR, Jr., Schwartz JM, Bergman KS, et al: Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatr 49:681-689, 1992
30. Bench CJ, Friston KJ, Brown RG, et al: The anatomy of melancholia - Focal abnormalities of cerebral blood flow in major depression. Psychol Med 22:607-615, 1992
31. Sackeim HA, Prohovnik I, Moeller JR, et al: Regional cerebral blood flow in mood disorders. I. Comparison of major depressives and normal controls at rest. Arch Psychiatr 47:60-70, 1990
32. Frith CD, Friston KJ, Liddle PF, et al: A PET study of word finding. 29:1137-1148, 1991
33. Lucki I: The spectrum of behaviors influenced by serotonin. Biol Psychiatr 44:151-162, 1998
34. Mann JJ: Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 21:99S-105S, 1999
35. Shaskan EG, Snyder SH: Kinetics of serotonin accumulation into slices from rat brain: Relationship to catecholamine uptake. J Pharmacol Exp Ther 175:404-718, 1970
36. Soucy JP, Lafaille F, Lemoine P, et al: Validation of the transporter ligand cyanoimipramine as a marker of serotonin innervation density in brain. J Nucl Med 35:1822-1830, 1994
37. Ramamoorthy S, Blakely RD: Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285:763-746, 1999
38. Mann JJ, Huang YY, Underwood MD, et al: A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal-cortical binding in major depression and suicide. Arch Gen Psychiatry 57:729-838, 2000
39. Arango V, Underwood MD, Boldrini M, et al: Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 25:892-903, 2001
40. Malison RT, Price LH, Berman R, et al: Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane and single photon emission computed tomography. Biol Psychiatr 44:1090-1098, 1998
41. Staley JK, Berman RM, Malison RT, et al: Follow-up study of midbrain serotonin transporter binding in major depression as measured by [I-123]-beta-CIT SPECT. J Nucl Med 40:143P, 1999 (abstr)
42. Willeit M, Praschak-Rieder N, Neumeister A, et al: [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatr 47:482-489, 2000
43. Meyer JH, Wilson AA, Ginovart N, et al: Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study. Am J Psychiatr 158:1843-1849, 2001
44. Ichimiya T, Suhara T, Sudo Y, et al: Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. Biol Psychiatr 51:715-722, 2002
45. LeDoux JE: Emotional memory systems in the brain. Behav Brain Res 58:69-79, 1993
46. Schneider F, Gur RE, Mozley LH, et al: Mood effects on limbic blood flow correlate with emotional self-rating: A PET study with oxygen-15 labeled water. Psychiatr Res 61:265-283, 1995
47. Sheline YI, Sanghavi M, Mintun MA, et al: Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 19:5034-5043, 1999
48. Drevets WC, Videen TO, Price JL, et al: A functional anatomical study of unipolar depression. Neurosci 12:3628-3641, 1992
49. Abercrombie HC, Schaefer SM, Larson CL, et al: Metabolic rate in the right amygdala predicts negative affect in depressed patients. Neuroreport 9:3301-3307, 1998
50. Drevets WC: Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 877:614-637, 1999
51. Drevets WC, Price JL, Bardgett ME, et al: Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav 71:431-477, 2002
52. Boldrini M, Underwood MD, Hsiung S, et al: Fewer serotoning transporter mRNA expressing neurons in the dorsal raphe nucleus of suicide victims. Soc Neurosci 25:1798, 1999 (abstr)
53. Austin M, Whitehead R, Edgar C, et al: Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience 114:807-815, 2002
54. Lesch KP, Mayer S, Disselkamp-Tietze J, et al: 5-HT1A receptor responsivity in unipolar depression: Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatr 28:620-628, 1990
55. Shiah IS, Yatham LN, Lam RW, et al: Cortisol, hypothermic, and behavioral responses to ipsapirone in patients with bipolar depression and normal controls. Neuropsychobiology 38:6-12, 1998
56. Moeller FG, Steinberg JL, Fulton M, et al: A preliminary neuroendocrine study with buspirone in major depression. Neuropharmacology 10:75-83, 1994
57. Mobayed M, Dinan TG: Buspirone/prolactin response in post head injury depression. J Affective Disord 19:237-241, 1990
58. Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression [see comments]. Arch Gen Psychiatr 54:597-606, 1997
59. Sapolsky RM: The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatr 48:755-65, 2000
60. Lopez JF, Chalmers DT, Little KY, et al: A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatr 43:547-73, 1998
61. Maines LW, Keck BJ, Smith JE, et al: Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain. Synapse 32:58-66, 1999
62. Pike VW, McCarron JA, Lammertsma AA, et al: Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635. Eur J Pharmacol 301: R5-7, 1996
63. Farde L, Ginovart N, Ito H, et al: PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain. Psychopharmacology (Berl) 133:196-202, 1997
64. Parsey RV, Slifstein M, Hwang DR, et al: Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab 20:1111-1133, 2000
65. Sargent PA, Kjaer KH, Bench CJ, et al: Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatr 57:174-180, 2000
66. Drevets WC, Frank E, Price JC, et al: PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatr 46:1375-1387, 1999
67. Farde L, Wiesel FA, Stone-Elander S, et al: D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatr 47:213-219 1990
68. Wong DF, Wagner H, Jr, Pearlson G, et al: Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: A preliminary report. Psychopharmacol Bull 21:595-598, 1985
69. Breier A, Su TP, Saunders R, et al: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574, 1997
70. Nordstrim A-L, Farde L, Wiesel F-A, et al: Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatr 33:227-235, 1993
71. Martinez D, Mawlawi O, Hwang D, et al: Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: Preliminary analyses. Nucl Med Biol 27:523-527, 2000
72. Martinez D, Hwang D, Mawlawi O, et al: Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 24:209-29, 2001
73. Rabiner EA, Bhagwagar Z, Gunn RN, et al: Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatr 158:2080-2082, 2001
74. Sargent PA, Kjaer KH, Bench CJ, et al: Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635. Effects of depression and antidepressant treatment. Arch General Psychiatr 57:174-180, 2000
75. Owens MJ, Knight DL, Nemeroff CB: Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatr 47:842-845, 2000